Does the Number of Donor Specific Antibodies Crossed at the Time of Heart Transplant Impact Post-Transplant Outcome?

Purpose: Most heart transplant programs do not cross donor-specific antibodies (DSA) at the time of transplant due to risk of hyperacute rejection or delayed hyperacute rejection as well as increased risk of antibody-mediated rejection (AMR) in the first year after heart transplant. Other programs have been crossing DSA if they are at low level (less than 5000 MFI). Post-transplant therapy such as anti-thymocyte globulin and intravenous immune globulin have been reported to be helpful to prevent AMR.

Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: J. Kobashigawa, M. Kittleson, E. Kransdorf, , G. Jamero, A. Kanungo, M. Lee, N. Bhatnagar, L. Stern, A. Nikolova, L. Czer, F. Esmailian, J. Patel Source Type: research